Présentation de l'entreprise
Flora Growth Corp. operates within the financial services sector, specifically functioning as an asset management entity that leverages artificial intelligence to provide decentralized AI solutions while also distributing pharmaceutical goods and medical cannabis products for various health indications, including cancer therapies. The company is positioned in the asset management industry, which implies a focus on managing capital and potentially providing investment strategies, although its operational scope extends into healthcare distribution. ZeroStack Corp. currently maintains a market capitalization of $21.59M and generates annual revenue of $57.61M, supported by a workforce of 64 employees. These financial figures indicate that the company operates as a small-cap entity with significant top-line growth relative to its size, suggesting a business model that prioritizes revenue expansion over immediate profitability, a common characteristic in emerging sectors or companies transitioning through early-stage development.
Santé financière
The company reported a revenue of $57.61M for the trailing twelve months, yet recorded a net income of $-15,921,000 and an EBITDA of $-13,713,000. The substantial gap between the $57.61M revenue and the negative net income reveals a cost structure where operating expenses significantly exceed gross profits, indicating high burn rates typical of growth-stage companies or those in capital-intensive distribution models. Free cash flow stands at $-4,575,625, which signifies that the company is consuming cash reserves to fund its operations and growth initiatives rather than generating surplus cash for distribution to shareholders. The gross margin is 21.0%, while the operating margin is -33.5% and the profit margin is -27.7%; these figures collectively indicate that while the core business retains a portion of revenue after direct costs, overhead and operational expenses are eroding profitability to the point where the company is losing money on every dollar of sales. The balance sheet shows $13.10M in cash against $3.25M in debt, resulting in a debt-to-equity ratio of 5.00, which suggests a highly leveraged position where equity capital is minimal relative to liabilities. Despite the leverage, the current ratio of 2.08 indicates that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity to manage obligations without immediate distress. Return on Equity is -45.3% and Return on Assets is -17.5%, metrics that reveal that management is currently destroying value rather than generating returns, likely due to the heavy investment required to scale the decentralized AI infrastructure and medical distribution networks.
Évaluation de la valorisation
The P/E Ratio (TTM) is listed as N/A due to the negative earnings, while the Forward P/E is -8.52, implying that the market is pricing in expectations of future earnings normalization or continued losses that will not be reflected in standard trailing multiples. The Price to Book ratio is 0.10, which indicates that the market values the company at a fraction of its book value, suggesting that the market assigns a discount to the firm's tangible assets, possibly reflecting the intangible nature of its AI technology or the risks associated with its medical distribution business. The Price to Sales ratio is 0.37 and the EV/EBITDA is 0.08; these alternative valuation metrics suggest that the company is trading at a very low multiple relative to its revenue and enterprise value, often seen in distressed or high-growth speculative assets where traditional earnings-based valuation is not applicable. The 52-week high is $47.00 and the 52-week low is $5.86, and without a specific current price in the provided facts, the valuation context is defined by this extreme volatility range. The Beta is 1.90, which means the stock's price volatility is nearly double that of the broader market, indicating that investors face significantly higher risk exposure when holding this asset compared to the general equity market.
Growth & Income
Revenue Growth (YoY) is 34.7%, whereas Earnings Growth (YoY) is N/A because the company is currently reporting negative earnings; this dynamic implies that revenue expansion is outpacing any path to profitability, but the lack of positive earnings growth makes standard growth comparisons impossible at this stage. As the company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it does not distribute cash to shareholders, meaning the 0.0% payout ratio is technically sustainable but non-existent as the firm reinvests all available resources back into the business rather than paying dividends. The overall growth and income profile is characterized by aggressive top-line expansion accompanied by significant cash burn and a complete absence of shareholder distributions. The company's financial strategy focuses entirely on scaling operations and developing its AI and medical product lines, foregoing current shareholder income to potentially build a more robust revenue base in the future.